INDO AMERICAN JOURNAL OF PHARMACEUTICAL RESEARCH

INCREASED RISK OF ENDOMETRIAL CARCINOMA AND ACCURACY IN THE DIAGNOSIS OF PATIENTS: A GYNECOLOGIC STUDY

Matta Jyothi Sravani, Guvvala Gayathri, A. Deevan Paul*
SVU College of Pharmaceutical Sciences, SV University, Tirupati- 517502.

ARTICLE INFO

Article history
Received 27/10/2017
Available online
06/12/2017

Keywords
Endometriosis,
Chemotherapy,
Oestrogen,
Tumorigenesis.

ABSTRACT

In sharp difference to numerous other tumor sorts, the occurrence and mortality of endometrial disease keep on growing. This awful pattern is, in no little section, an aftereffect of the overall corpulence pandemic. The greater part of endometrial tumor as of now owing to heftiness, which is perceived as an autonomous hazard factor for this sickness. In this survey, we recognize the sub-atomic systems by which heftiness and fat tissue add to the pathogenesis of endometrial growth. We additionally talk about the effect of stoutness on the clinical administration of the malady and look at the improvement of normal behavioural and pharmaceutical intercessions went for diminishing endometrial tumor chance, enhancing malignancy results, and saving fruitfulness in an inexorably more youthful populace of patients with endometrial growth.

Corresponding author
A. Deevan Paul
SVU College of Pharmaceutical Sciences
SV University, Tirupati – 517502.
deevan4@gmail.com

*Please cite this article in press as **Matta Jyothi Sravani** et al. Increased Risk of Endometrial Carcinoma and Accuracy in the Diagnosis of Patients: A Gynecologic Study. Indo American Journal of Pharmaceutical Research.2017:7(11).*

INTRODUCTION

Endometrial disease is the fourth most regular tumor in ladies with an expected 46,470 new findings and more than 8000 passing's as of late. Rate of endometrial malignancy is on the ascent with a lifetime danger of around 3%. Most strikingly, 5-year survival is presently fundamentally more regrettable than 30 years back (84% survival in 2006 versus 88% survival in 1975), making endometrial disease just a single of two growths with expanded mortality [1]. This is stark in contrast with bosom and prostate tumor, where 5-year survival has significantly enhanced to less than 90% for bosom and 100% for prostate malignancy. For patients with beginning time sickness, hysterectomy is viewed as corrective. By differentiate, propelled stage and high review endometrial tumor is deadly. Certain hazard factors have been all around described, for example, menopausal status, stoutness, diabetes, hypertension and unopposed oestrogen, however for some of these hazard factors, for example, heftiness, the components by which this happens are not totally understood [2]. In this section, we depict the flow hones for finding and treatment of endometrial tumor and examine rising helpful techniques that are would have liked to enhance survival and turn around the disturbing rising pattern of this illness.



Figure No.1: Mutation profiles of clear cell endometrial cancer.

Among women, obesity is more strongly associated with the development of endometrial cancer than any other cancer type [3]. In fact, approximately 57% of endometrial cancers in the United States are thought to be attributable to being overweight and obese [4-5]. This association has been well established and follows a dose-response relationship, with the incidence of endometrial cancer increasing as body mass index (BMI) increases. In a meta-analysis of 26 studies by the American Institute for Cancer Research, for every increase of five BMI units, there was a 50% increase in the risk of developing endometrial cancer [6]. Endometriosis endometrial cancer is the histologic subtype predominantly linked to obesity; however, the incidence of more aggressive, non-endometrioid subtypes (such as serous, clear cell, and carcinosarcoma) has also recently been found to increase with increasing BMI [7].

Once determined to have endometrial growth, being hefty predicts more regrettable results. Contrasted and ladies with an ordinary BMI, the RR of ailment particular mortality for stout ladies with a BMI of 30 to 34.9 kg/m2 is 2.53, and significantly more strikingly, for butterball shaped ladies with a BMI more prominent than 40 kg/m2, the RR is 6.25. Furthermore, corpulence negatively affects all-cause mortality. In a review investigation of ladies with early endometrial disease, very big boned ladies had higher death rates contrasted and ladies with an ordinary BMI, and 67% of these passing's were an aftereffect of noncancerous, stoutness related causes. As rates of corpulence among ladies keep on increasing, the frequency of endometrial growth is relied upon to increase [8-10].



Figure No 2: Surgical pathology images of polypoid masses into the endometrial cavity.

A multivariate linear regression model, which accounts for expected changes in obesity, hysterectomy rates, and smoking tobacco, predicts that by the year 2030, the incidence of endometrial cancer will reach 42.13 cases per 100,000 women. This represents a staggering 55% increase over the incidence in 2010 [11]. Despite the clear evidence linking endometrial cancer and obesity, there is limited public awareness of this relationship. In a survey of 1,545 healthy women, 58% of participants were not aware that obesity increased the risk for developing endometrial cancer. Women diagnosed with endometrial cancer or complex atypical hyperplasia (CAH), a precursor lesion to endometrial cancer, do not fare much better. One survey that included 43 women with endometrial cancer or CAH revealed that 46.5% of the women were unaware that obesity was a risk factor for their disease. Furthermore, oncologists and other health care providers are often reluctant to counsel patients with endometrial cancer about obesity. In a separate survey of 108 women with endometrial cancer, only29% reported being told by their health care provider about the link between obesity and developing endometrial cancer. Interestingly, all of the women who were counselled about obesity by their oncologists attempted to lose weight [12-14]. Although the association is not as strong as with endometrial cancer, it is interesting to note that the risk of developing other gynaecologic malignancies may also be affected by obesity. Although the data have been mixed in prior studies, in a recent meta-analysis of 25 studies of more than 15,000 women, for every increase of five BMI units observed, there was a 6% increased risk in developing ovarian cancer. A case-control study in France suggests that central adiposity (as measured by waist-to-hip circumference) may be a stronger risk factor for ovarian cancer than obesity as measured by BMI alone [15-16]. This relationship warrants additional study.

STAGING

In 2009, the International Federation of Gynaecology and Obstetrics (FIGO) changed the organizing framework for carcinomas of the vulva, cervix, and endometrium [17-18]. The essential changes made for endometrial tumor incorporated the gathering of stages IA and IB together as stage IA with the loss of earlier IC and the division of stage IIIC (metastasis to the pelvic and/paraaortic lymph hubs) into arrange IIIC1 (positive pelvic hubs) and IIIC2 (positive paraaortic lymph hubs). Particularly the old organizing framework characterized arrange IA as no intrusion into the myometrium, organize IB as under half attack into the myometrium, and stage IC as equivalent to or more prominent than half attack into the myometrium, while the new FIGO 2009 framework characterizes arrange IA as disease limited to the uterus with under half myometrial attack, and stage IB as equivalent to or more noteworthy than half myometrial intrusion, with both IA and IB including any tumor review. This was changed after information from the FIGO Annual Report demonstrated no distinction in survival between past stage IA review 1 or 2 and stage IB review 1 or 2 tumours'. The other noteworthy change included patients with positive pelvic or para-aortic lymph hubs. Under the old FIGO rules, patients with positive pelvic and additionally paraaortic lymph hubs were arranged as IIIC, and under the new framework patients with positive pelvic lymph hubs are isolated from those with positive paraaortic +/−pelvic lymph hubs, organize IIIC1 and IIIC2, separately. This change was aggravated on the grounds that many investigations exhibited survival for patients with positive paraaortic lymph hubs when contrasted with positive pelvic lymph hubs [19-21].



Fig No.3: Endometrial cancer included the grouping of stages IA and IB.

RISK STRATIFICATION AND ADJUVANT THERAPY:

For those patients who have undergone an appropriate staging and treatment surgery, adjuvant RT (vaginal brachytherapy or external beam), chemotherapy or hormonal therapy may be recommended depending upon risk factors. Patients are categorized based upon risk stratification in the post-operative period. Low and low-intermediate-risk patients may not require post-surgical therapy; however, molecular risk factors such as 53 mutations, etc. if known, may impact this decision. Given the potential side effects of adjuvant therapy, it is important to distinguish between patients who would benefit from adjuvant therapy and those who would be better served simply by close clinical follow up. Those of high-intermediate-risk require post-surgical treatment with RT to reduce local recurrence based upon the fact that 75% of recurrences are in the pelvis. Currently, there is no well-established treatment protocol for patients with advanced-stage disease, although this is the subject of clinical trials. Patients at high risk require adjuvant treatment, which is most often RT for high risk cases confined to the uterus and chemotherapy for cases with extrauterine disease. Large prospective clinical trials have demonstrated that post-operative pelvic radiation therapy does decrease local recurrences, but has no overall impact on survival. Many clinicians had concerns regarding the side effects of whole pelvic radiation in treating patients with early stage endometrial cancer. Recent evidence from PORTEC-2 demonstrates that the use of vaginal brachytherapy is no worse that whole pelvic radiation therapy, and as a result of this trial many centres within the United States have shifted to the use of vaginal brachytherapy for their patients in whom adjuvant radiation therapy is warranted [22-24].

PORTEC 1 (intermediate)	IBgr2-3 ICgr1-2	TAHBSO	NAT vs EBRT	Locoregional recurrence 4% vs 14% (P <0.001)	Survival 81% vs 85%	Severe complications 3% GI at 5 yrs
PORTEC 2 (high risk-intermediate)	IB gr 3 IC gr 1-2 IIA	TAHBSO	EBRT vs VBT	2% vs 5%	80% vs 85%	acute GI 13% vs 54%
ASTEC/EN5	I AB gr 3 IC II, serous, CC	TAHBSO ± lymphadenect.	NAT vs EBRT	4% vs 7% (p=o.039)	84 % vs 84%	3% vs 7% gr 3-4

Figure No. 4: Treatment of choice for intermediate high-risk patients.

Long-term follow up studies for PORTEC-1 and PORTEC-2 have demonstrated more urinary and bowel dysfunction for patients treated with whole pelvic radiation therapy (PORTEC-1) and, as expected, patients who received vaginal brachytherapy exhibited fewer adverse effects than those who received pelvic radiation (PORTEC-2) (25-26). Obesity is clearly a risk factor for the development of endometrial cancer, but the mechanisms by which this occurs are not well understood. While production of estrone from the adipose tissue with local conversion to oestradiol in the endometrium is one hypothesis, recent publications point to a genetic link between obesity and endometrial cancer. For example, an association between single nucleotide polymorphisms in genes related to obesity and endometrial cancer was recently made (27-28). Much information remains to be understood about the relationship between obesity and endometrial cancer, and support for these efforts are being recognized by the National Cancer Institute (NCI) and other funding agencies, as is reflected by the NCI's recent request for applications directly related to obesity.

CHEMOTHERAPY:

Chemotherapy is the treatment of choice for metastatic disease. The choice of the regimen has evolved over the past decade. The most active agents are anthracyclines, platinum compounds. As single agents, these drugs result in a response rate greater than 20%. Single agent chemotherapy is an option for patients who are likely to have unacceptable side effects with multiple agents. However, for the majority of patients, multiple agents are used. Response rates for triple therapy with doxorubicin, cisplatin and paclitaxel were 57% in GOG 177, however, side effects were prominent. Phase II trials indicate that the double combination of cisplatin and paclitaxel results in a relatively high rate of response, and this regimen appears to be better tolerated [29-31]. A comparison between the triple and double combination regimens with and without doxorubicin is currently underway in GOG 209, and the results are pending

UNOPPOSED OESTROGEN AND RELATIONSHIP BETWEEN OBESITY AND ENDOMETRIAL CANCER:

In premenopausal ladies, the cyclic articulation of oestrogen by the ovaries drives endometrial multiplication. After menopause, fringe tissues, particularly fat tissue, turn into the principle site of oestrogen union. Adiposities, preadipocytes, and mesenchymal undifferentiated organisms inside fat tissue are the transcendent wellspring of aromatase, the compound in charge of the transformation of androgens to oestrogen. Aromatase levels and action increment as an element of age and adiposity [32-37] and, thusly, add to oestrogen-incited endometrial multiplication in the postmenopausal woman [38-39]. Furthermore, sex hormone–restricting globulin (SHBG) levels diminish with expanding adiposity, in this manner expanding the pool of bioactive oestrogen, even without all over again oestrogen combination.

Oestrogen acts not only as a mitogen, but also as a mutagen. Genotoxic metabolites of oestrogen react with DNA to form depurination adducts, ultimately producing an accumulation of double-stranded DNA breaks and contributing to genetic instability (40-45). Although the role of oestrogen metabolites in the pathogenesis of breast cancer is well characterized, their role in the context of endometrial cancer is not. Approximately a third of endometrial cancers demonstrate DNA mismatch repair defects, as a result of somatic methylation of MLH1 or, less frequently, Lynch syndrome (46-49).Therefore, localized exposure of the endometrium to estrogen metabolites is more likely to produce genetic mutations contributing to tumorigenesis in the absence of functional DNA repair systems.

MECHANISTIC PATHWAYS LINKING OBESITY TO ENDOMETRIAL CANCER:

Visceral fat is a complex endocrine organ, composed of adipocytes and preadipocytes, as well as infiltrating macrophages, stromal, nerve, and stem cells. Together, they secrete an array of adipokines that exert localized and systemic effects, which increase endometrial proliferation and promote tumorigenesis [50-54]. Furthermore, adipose tissue is a source [55-56].



(A) **(B).**

Fig No.5: (A)Effects of obesity on endometrial proliferation and tumorigenesis. (B) The interplay between the obesity and cancer.

Obesity contributes to the increased risk of endometrial cancer in the postmenopausal uterus by a variety of mechanisms. Increased adiposity increases aromatase activity, which leads to the conversion of androgens to oestrogens, to directly promote endometrial proliferation and transcription of proliferative genes. The chronic inflammation associated with visceral adiposity is mediated by proinflammatory adipokines and leads to hyperinsulinemia, increases in insulin-like growth factor 1 (IGF1), and hyperglycaemia, which fuel endometrial proliferation. A concurrent decrease in anti-inflammatory cytokines is also observed. Inflammation and an increase in oestrogen metabolites further contribute to DNA damage and genetic instability. Finally, stem cells can be recruited from adipose tissue, where they contribute to a supportive tumor microenvironment. ER, oestrogen receptor; IGF1R, insulin like growth factor 1 receptor; IR, insulin receptor; IRS, insulin receptor substrate; mTOR, mammalian target of rapamycin.

SURGICAL TREATMENT:

Multiple studies have addressed the potential benefit of secondary cytoreductive surgery on overall survival in patients with recurrent endometrial cancer. Whether recurrent endometrial cancer is localised to the pelvis or disseminated throughout the abdomen, secondary cytoreduction has been shown to improve both progression- free and overall survival. More specifically, survival seems to be dependent on the type of recurrence (solitary recurrence vs carcinomatous), the ability to achieve optimal cytoreduction and the time from original treatment to recurrence. Median overall survival after secondary cytoreductive surgery for recurrent endometrial cancer ranges from 39 to 57 months after surgery. In previously irradiated patient with localized recurrence, pelvic eventration remains the only curative option, although it is associated with significant postoperative morbidity (60%-80%) and even mortality (10%-15%). Despite such high postoperative morbidity, the reported 20% to 40% 5-year survival rates makes pelvic exenteration the only curative option and may justify the radically of the approach.

Surgical treatment in stage I endometrial cancer:

In an Italian study, 514 patients with stage I endometrial cancer were randomised to receive lymphadenectomy or not (excluding stage IA–IB G1 and non-endometrioid isotope). In this study, systematic lymphadenectomy did not improve disease-free or overall survival. In the ASTEC trial, 1408 women with malignancies confined to the uterus were randomised. In this trial, there was no evidence of a benefit on overall survival or recurrence-free survival when pelvic lymphadenectomy was carried out. The authors concluded that routine systematic pelvic lymphadenectomy cannot be recommended in women with stage I endometrial cancer, unless enrolled in clinical trials. However, the design of these studies has not addressed the most important impact of lymphadenectomy in the high-risk population in order to identify patients who can safely avoid or benefit from adjuvant treatment .A large retrospective study published in 2010, comparing systematic pelvic lymphadenectomy versus systematic pelvic and para-aortic lymphadenectomy (SEPAL study), has suggested that overall survival was significantly longer in patients undergoing pelvic and para-aortic lymphadenectomy . The SEPAL study suggests that high-risk patients may benefit from aggressive surgery. Sentinel lymph node identification in endometrial cancer has been described, with interesting preliminary results, which deserve further investigation in properly designed clinical studies. Further randomised trials will be focused on investigating the role of lymphadenectomy for patients with high-risk endometrial cancer to direct subsequent treatment and the role of sentinel node biopsy.

Surgical treatment in stage II endometrial cancer:

Traditionally, the surgical approach consists of radical hysterectomy with bilateral salpingo-oophorectomy and systematic pelvic lymphadenectomy with or without para-aortic lymphadenectomy. In stage II, lymphadenectomy is recommended to guide surgical staging and adjuvant therapy.

Surgical treatment in stage III–IV endometrial cancer:

Maximal surgical debulking is indicated in patients with a good performance status and respectable tumour [III, B]. For distant metastatic disease, palliative surgery could be considered in patients with a good performance status. When surgery is not feasible due to medical contraindications (5%–10% of patients), or because of irresectable disease, external radiation therapy with or without intracavitary brachytherapy to the uterus and
vagina is suitable for individual clinical use.

Treatment of endometrial carcinoma

			Surg	RT	Chemo
Local'zd	I	uterus	Yes*	Adj RT may (G3 or IB/C)	Adj CT may (G3 + IC/IB)
	II	cervix	Yes * OR‡	adjRT in all RT then Surg	Adj CT in G3
extraut	IIIA	abdomen	Yes	adj RT	Adj CT in G3
	IIIB IVA	Pelvis vag/param /bladd/rectm	May after RT	RT	may
mets	IVB	mets	yes	May	Palliative CT OR hormonal T

Figure No.6 Endometrial cancer in the surgical treatment.

POTENTIAL LIFE STYLE INTERVENTIONS:

Public health interventions that decrease the overall prevalence of obesity may have the greatest impact on decreasing endometrial cancer rates in the population. On an individual basis, however, although lifestyle interventions for weight loss may theoretically reduce a woman's risk for developing endometrial cancer, the data to support this are still lacking. There are a limited number of studies evaluating the effect of diet on endometrial cancer risk, and the findings have been mixed at best. Two large meta-analyses have shown that diets with a high glycaemic load significantly increase the risk of developing endometrial cancer[57-58],and a review of three case-control studies suggests that a Mediterranean diet may be associated with a decreased risk of endometrial cancer [59].However, a recent prospective analysis of participants in the Women's Health Initiative showed that quality of diet (as measured by four diet quality indices) had no impact on the development of endometrial cancer. Two additional analyses examining the healthy eating index (based on the Dietary Guidelines for Americans) and the Recommended Foods Score showed no association between adhering to these diets and developing endometrial cancer [60]. There are even fewer studies examining the relationship between exercise and ovarian cancer risk. High-quality prospective studies are needed to better understand the role of these potential lifestyle interventions on the risk of developing ovarian cancer.

FOLLOW-UP CARE AND SURVIVORSHIP:

When you have been dealt with for endometrial growth, you should be nearly taken after for a repeat. At to begin with, you will have follow-up visits off and on again. The most astounding possibility for a repeat is in the initial 3 years after conclusion. In woman's with generally safe ailment, there has a tendency to be a little danger of repeat (under 5%). Around 40% of repeats are neighbourhood (close where the tumor was) and 60% are far off (to different organs). The greater part of repeats (70%) happen at the highest point of the vagina and cause side effects, for example, vaginal dying, stomach agony, or weight reduction, and these ought's to be accounted for to one's human services supplier promptly on the off chance that they happen. The more you are free of ailment, the less frequently you should go for check-ups. Dread of repeat, connections and sexual wellbeing, budgetary effect of malignancy treatment, business issues and adapting systems are regular passionate and pragmatic issues experienced by endometrial growth survivors. A survivorship mind design can be an initial phase in teaching yourself about exploring life after growth and helping you discuss proficiently with your social insurance suppliers [61-62].

CONCLUSION

The evidence for a connection between the use of conjugated Oestrogens and the development of endometrial cancer seems rather persuasive. Caution is urged, however in view of the absence of data both from similar epidemiologic studies in other populations and from follow-up studies. Such information is necessary before policy conclusions can be drawn. Further studies are necessary to evaluate the possible relation between the use of other oestrogens and endometrial cancer. Endometrial cancer is often detected at an early stage because it frequently produces abnormal vaginal bleeding, which prompts woman to see their doctors. If endometrial cancer is discovered early, removing the uterus surgically often cures endometrial cancer.

ACKNOWLEDGEMENT

The authors acknowledge the SVU College of Pharmaceutical Sciences, SV University, Tirupati.

REFERENCES

1. Schmandt RE, et al. Understanding obesity and endometrial cancer risk: opportunities for prevention. Am J Obstet Gynecol. 2011; 205(6):518–25.
2. Reeves GK, Pirie K, Beral V, et al: Cancer incidence and mortality in relation to body mass index intheMillion Women Study: Cohort study. BMJ 335: 1134, 2007.
3. Calle EE, Kaaks R: Overweight, obesity and cancer: Epidemiological evidence and proposed mechanisms. Nat Rev Cancer 4:579-591, 2004.
4. Renehan AG, Tyson M, Egger M, et al: Bodymassindex and incidence of cancer: A systematic review and meta-analysis of prospective observational studies. Lancet 371:569-578, 2008.
5. World Cancer Research Fund/American Institute for Cancer Research: Continuous Update Project Report. Food: Nutrition, Physical Activity, and the Prevention of Endometrial Cancer. 2013.
6. McCullough ML, Patel AV, Patel R, et al: Body mass and endometrial cancer risk by hormone replacement therapy and cancer subtype. Cancer Epidemiol Biomarkers Prev 17:73-79, 2008.
7. Calle EE, Rodriguez C, Walker-Thurmond K, et al: Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. NEngl J Med 348:1625-1638, 20037. vonGruenigen VE, Tian C, Frasure H, et al: Treatment effects, disease recurrence, and survival in obese womenwith early endometrial carcinoma: A Gynecologic Oncology Group study. Cancer 107: 2786-2791, 2006.
8. Flegal KM, Kruszon-Moran D, Carroll MD, et al: Trends in obesity among adults in the United States, 2005 to 2014. JAMA 315:2284-2291, 2016.
9. Sheikh MA,Althouse AD, Freese KE, et al: USA endometrial cancer projections to 2030: Should we be concerned? Future Oncol 10:2561-2568, 2014.
10. Soliman PT, Bassett RL, Jr, Wilson EB, et al: Limited public knowledge of obesity and endometrial cancer risk: What women know. Obstet Gynecol 112:835-842, 2008.
11. Beavis AL, Cheema S, Holschneider CH, et al: Almost half of women with endometrial cancer or hyperplasia do not know that obesity affects their cancer risk. Gynecol Oncol Rep 13:71-75, 2015.
12. Clark LH, Ko EM,Kernodle A, et al: Endometrial cancer survivors' perceptions of provider obesity counseling and attempted behavior change: Are we seizing the moment? Int J Gynecol Cancer 26:318-324, 2016.
13. World Cancer Research Fund/American Institute for Cancer Research: Continuous Update Project Report: Food, Nutrition, Physical Activity, and the Prevention of Ovarian Cancer 2014.
14. Delort L, Kwiatkowski F, Chalabi N, et al: Central adiposity as a major risk factor of ovarian cancer. Anticancer Res 29:5229-5234, 2009.
15. Renehan AG, Zwahlen M, Egger M: Adiposityand cancer risk: New mechanistic insights from epidemiology.Nat Rev Cancer 15:484-498, 2015.
16. Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet. 2009; 105(2):103–4. [PubMed: 19367689].
17. Mutch DG. The New FIGO staging system for cancers of the vulva, cervix, endometrium, and sarcomas. Gynecol Oncol. 2009; 115:325–328.

18. Creasman WT, et al. Carcinoma of the corpus uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006; 95(Suppl 1):S105–43. Gultekin M, et al. Comparison of FIGO 1988 and 2009 staging systems for endometrial carcinoma.Med Oncol. 2012.
19. Page BR, et al. Does the FIGO 2009 Endometrial Cancer Staging System More Accurately Correlate With Clinical Outcome in Different Histologies?: Revised Staging, Endometrial Cancer,Histology. Int J Gynecol Cancer. 2012.
20. Keys HM, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004; 92(3):744–51.
21. Creutzberg CL, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma.Lancet. 2000; 355(9213):1404–11.
22. Nout RA, et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet. 2010; 375(9717):816–23.
23. Nout RA, et al. Long-term outcome and quality of life of patients with endometrial carcinoma treated with or without pelvic radiotherapy in the post operative radiation therapy in endometrial carcinoma 1 (PORTEC-1) trial. J ClinOncol. 2011; 29(13):1692–700.
24. Nout RA, et al. Five-year quality of life of endometrial cancer patients treated in the randomised Post-Operative Radiation Therapy in Endometrial Cancer (PORTEC-2) trial and comparison with norm data. Eur J Cancer. 2011.
25. Delahanty RJ, et al. Association of obesity-related genetic variants with endometrial cancer risk: a report from the Shanghai Endometrial Cancer Genetics Study. Am J Epidemiol. 2011; 174(10): 1115–26.
26. Chen X, et al. Genetic polymorphisms in obesity-related genes and endometrial cancer risk. Cancer. 2011.
27. Fleming GF, et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 2004; 22(11):2159–66.
28. Hoskins PJ, et al. Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study. J ClinOncol. 2001; 19(20):4048–53.
29. Sorbe B, et al. Treatment of primary advanced and recurrent endometrial carcinoma with a combination of carboplatin and paclitaxel-long-term follow-up. Int J Gynecol Cancer. 2008; 18(4):803–8.
30. Mihm M, Gangooly S, Muttukrishna S: The normal menstrual cycle in women. AnimReprodSci 124:229-236, 2011.
31. Davis SR, Lambrinoudaki I, Lumsden M, et al: Menopause. Nat Rev Dis Primers 1:15004, 2015.
32. 35. Blakemore J, Naftolin F: Aromatase: Contributions to physiology and disease in women and men. Physiology (Bethesda) 31:258-269, 2016.
33. O'Connor KA, Ferrell RJ, Brindle E, et al: Total and unopposed estrogen exposure across stages of the transition to menopause. Cancer Epidemiol Biomarkers Prev 18:828-836, 2009
34. 37. Simpson ER, Mendelson CR: Effect of aging and obesity on aromatase activity of human adipose cells. Am J ClinNutr 45:290-295, 1987.
35. Bulun SE, Simpson ER: Regulation of aromatase expression in human tissues. Breast Cancer Res Treat 30:19-29, 1994.
36. Vicennati V, Garelli S, Rinaldi E, et al: Obesityrelatedproliferative diseases: The interaction between adipose tissue and estrogens in post-menopausal women. HormMol Biol ClinInvestig 21:75-87, 2015.
37. Zhao H, Zhou L,Shangguan AJ, et al: Aromatase expression and regulation in breast and endometrial cancer. J MolEndocrinol 57:R19-R33, 2016.
38. Simo´ R, Sa´ez-Lo´ pez C, Barbosa-Desongles A, et al: Novel insights in SHBG regulation and clinical implications. Trends EndocrinolMetab 26:376-383, 2015.
39. Simo´ R, Saez-Lopez C, Lecube A, et al: Adiponectinupregulates SHBG production: Molecular mechanisms and potential implications. Endocrinology 155:2820-2830, 2014.
40. Deng L,Feng J, Broaddus RR: The novel estrogen-induced gene EIG121 regulates autophagy and promotes cell survival under stress. Cell Death Dis 1:e32, 2010.
41. Westin SN, Broaddus RR, Deng L, et al: Molecular clustering of endometrial carcinoma based on estrogen-induced gene expression. Cancer Biol Ther8:2126-2135, 2009.
42. Cavalieri E, Chakravarti D, Guttenplan J, et al: Catechol estrogenquinones as initiators of breastand other human cancers: Implications for biomarkers of susceptibility and cancer prevention. BiochimBiophysActa 1766:63-78, 2006.
43. Cavalieri E, Rogan E: The molecular etiologyand prevention of estrogen-initiated cancers: Ockham's Razor: Pluralitas non estponenda sine necessitate. Plurality should not be posited without necessity. Mol Aspects Med 36:1-55, 2014.
44. Meyer LA, Broaddus RR, Lu KH: Endometrial cancer and Lynch syndrome: Clinical and pathologic considerations. Cancer Contr 16:14-22, 2009.
45. Batte BA, Bruegl AS, Daniels MS, et al: Consequences of universal MSI/IHC in screening endometrial cancer patients for Lynch syndrome. Gynecol Oncol 134:319-325, 2014
46. Tafe LJ, Riggs ER, Tsongalis GJ: Lynch syndrome presenting as endometrial cancer. ClinChem 60:111-121, 2014.
47. Mills AM, Longacre TA: Lynch syndrome: Female genital tract cancer diagnosis and screening. SurgPatholClin 9:201-214, 2016.
48. Renehan AG, Zwahlen M, Egger M: Adiposity and cancer risk: New mechanistic insights from epidemiology. Nat Rev Cancer 15:484-498, 2015.
49. Allott EH, Hursting SD: Obesity and cancer: Mechanistic insights from transdisciplinary studies. EndocrRelat Cancer 22:R365-R386, 2015.

50. Park J, Morley TS, Kim M, et al: Obesity and cancer: Mechanisms underlying tumour progression and recurrence. Nat Rev Endocrinol 10:455-465, 2014.
51. Khandekar MJ, Cohen P, Spiegelman BM: Molecular mechanisms of cancer development in obesity. Nat Rev Cancer 11:886-895, 2011.
52. Klopp AH, Zhang Y, Solley T, et al: Omentaladipose tissue-derived stromal cells promote vascularization and growth of endometrial tumors. ClinCancer Res 18:771-782, 2012 56. Pope BD, Warren CR, Parker KK, et al: Microenvironmental control of adipocyte fate and function. Trends Cell Biol 26:745-755, 2016.
53. Mulholland HG, Murray LJ, Cardwell CR, et al: Dietary glycaemic index, glycaemic load and breast cancer risk: A systematic review and meta-analysis. Br J Cancer 99:1170-1175, 2008.
54. Nagle CM, Olsen CM, Ibiebele TI, et al: Glycemicindex, glycemic load and endometrial cancer risk: Results from the Australian National Endometrial Cancer study and an updated systematic review and meta-analysis. Eur J Nutr 52:705-715, 2013.
55. Filomeno M, Bosetti C, Bidoli E, et al: Mediterraneandiet and risk of endometrial cancer: Apooled analysis of three Italian case-control studies. Br J Cancer 112:1816-1821, 2015
56. George SM, Ballard R, Shikany JM, et al: A prospective analysis of diet quality and endometrial cancer among 84,415 postmenopausal women in the Women's Health Initiative. Ann Epidemiol 25:788-793, 2015.
57. Chandran U, Bandera EV, Williams-King MG, et al: Adherence to the dietary guidelines for Americans and endometrial cancer risk. Cancer Causes Control 21:1895-1904, 2010.
58. Mai V, Kant AK, Flood A, et al: Diet quality and subsequent cancer incidence and mortality in a prospective cohort of women. Int J Epidemiol 34:54-60, 2005.
59. Itamochi H. Targeted therapies in epithelial ovarian cancer: Molecular mechanisms of action. World J Biol Chem. 2010; 1(7):209–20.
60. Temkin SM, Fleming G. Current treatment of metastatic endometrial cancer. Cancer Control. 2009; 16(1):38–45. [PubMed: 19078928]
61. Leslie KK, et al. Tyrosine kinase inhibitors in endometrial cancer. Int J Gynecol Cancer. 2005.,15:409–11.
62. Zagouri F, et al. Endometrial cancer: what is new in adjuvant and molecularly targeted therapy Obstet Gynecol Int. 2010; 2010:749579.